课题基金 / 基金详情

Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemia

Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemia
开发用于治疗急性髓性白血病的 FMS 样酪氨酸激酶受体 3 的不可逆共价抑制剂
批准号:
10081364
负责人:
Ping Cao
金额:
$29.89万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-18 至 2023-08-31

项目摘要

项目成果

Ping Cao的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 急性髓系白血病(AML)是一种发生在骨髓中的恶性造血祖细胞疾病。 在成人最常见的癌症中,占所有癌症的1%。AML通常在晚年被诊断出来 60岁及以上的人的长期存活率只有5%-15%。白纹伊蚊的细胞遗传学分析 诊断时的异常细胞已被证明是治疗成功的一个很好的指标 预后。有几个突变与AML有关,其中最常见的是FMS样突变 酪氨酸激酶3(Flt3)基因促进细胞因子非依赖性AML细胞存活和 扩散。目前有两种FDA批准的酪氨酸激酶抑制剂(TKI)用于治疗 Flt3突变;然而,研究表明,60%以上的人对这些药物缺乏反应。 以及由于非靶标毒性引起的一些副作用。Bridgene生物科学正在开发一种新的 将化学实体作为Flt3的小分子共价抑制剂,以解决FDA- 已批准的和正在开发的Flt3抑制剂。共价的Flt3抑制剂具有更高的效力, 与目前的非共价Flt3抑制剂相比,具有选择性和更长的停留时间,并可治疗耐药 突变,从而为AML提供了更有效和更安全的治疗选择。Bridgene Biosciences的Flt3 被称为BGS2456的抑制剂在体外对AML细胞株具有选择性生长抑制活性 由不同的Flt3癌基因突变体驱动。这些初步努力为 执行拟议的第一阶段计划,目的是为BGS2456的使用获得概念验证 作为治疗急性髓系白血病的同类最佳Flt3抑制剂。目标1的目的是增强药物的类药物特性 BGS2456通过药物化学方法。合成衍生品(目标1A)将按照 为效力、选择性(目标1B)和一些其他属性预先确定的指标,以评估其潜力 成为药物(目标1C),用标准的体外试验测定。顶级衍生品将升级 目标2,重点是利用AML细胞表征这些衍生物的体外效力和选择性 LINE(目标2A和2B)和评估血液毒性(目标2C)。一个单一的铅衍生物将被推进到目标3, 其目的是获得体内概念验证,用于在治疗中使用铅BGS2456衍生物 AML。最初,将执行PK和耐受性研究(目标3A)以告知给药,然后将衍生品 评估体内疗效,其定义为提高存活率和减少疾病进展 在AML小鼠模型(AIM 3B)中与吉特替尼(FDA批准的Flt3 TKI)进行比较。成功完成 拟议的第一阶段方案将支持第二阶段项目,重点是完成关键 药理和安全性评估研究,以生成目标产品简介,供 新型共价Flt3抑制剂治疗急性髓系白血病。
英文摘要
PROJECT SUMMARY Acute myeloid leukemia (AML), a malignant disease of hematopoietic precursor cells in the bone marrow, is one of the most common cancers in adults accounting for 1% of all cancers. AML is typically diagnosed later in life with individuals 60 and older having a long-term survival rate of merely 5-15%. Cytogenic analysis of the abnormal cells at the time of diagnosis has proven to be an excellent indicator of treatment success as well as prognosis. Several mutations are associated with AML with the most common ones being in the FMS-like tyrosine kinase 3 (FLT3) gene leading to the promotion of cytokine independent AML cell survival and proliferation. There are currently two FDA-approved tyrosine kinase inhibitors (TKIs) for treating patients with FLT3 mutations; however, studies have shown a significant lack of response to these drugs in upwards of 60% of patients and a number of side effects due to off-target toxicities. BridGene Biosciences is developing a new chemical entity to serve as a small-molecule covalent inhibitor of FLT3 in order to address the limitations of FDA- approved FLT3 inhibitors and those under development. A covalent FLT3 inhibitor has higher potency, selectivity, and longer residence time than current non-covalent FLT3 inhibitors, and treat drug-resistant mutations, thus providing a more effective and safe treatment option for AML. BridGene Biosciences’ FLT3 inhibitor, known as BGS2456, has demonstrated selective in vitro growth inhibition activity against AML cell lines driven by different FLT3 oncogenic mutants. These preliminary efforts provide significant support for the execution of the proposed Phase I program with the goal of obtaining proof-of-concept for the use of BGS2456 as a best-in-class FLT3 inhibitor for AML. The objective of Aim 1 is to enhance the drug-like properties of BGS2456 through a medicinal chemistry approach. Synthesized derivatives (Aim 1A) will be ranked according to pre-determined metrics for potency, selectivity (Aim 1B), and a few other properties to assess their potential to become drugs (Aim 1C) as determined using standard in vitro assays. The top derivatives will be advanced to Aim 2, which is focused on characterizing the in vitro potency and selectivity of the derivatives using AML cell lines (Aims 2A & 2B) and assessing hematotoxicity (Aim 2C). A single lead derivative will be advanced to Aim 3, which is geared toward obtaining in vivo proof-of-concept for the use of a lead BGS2456 derivative in treating AML. Initially, PK and tolerability studies (Aim 3A) will be executed to inform dosing then the derivative will be assessed for in vivo efficacy, which will be defined as enhanced survival and reduction in disease progression compared to gilteritinib (an FDA-approved FLT3 TKI) in an AML mouse model (Aim 3B). Successful completion of the proposed Phase I program will support a Phase II project that is focused on completing key pharmacological and safety assessment studies in order to generate a target product profile for the use of the novel covalent FLT3 inhibitor in treating AML.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Chemical Proteomics Platform to Expand Druggable Space
  • 批准号:
    9883136
  • 项目类别:
  • 资助金额:
    $16.83万
  • 财政年份:
    2018
  • 负责人:
    Ping Cao
  • 依托单位:
海外基金